In other drug development news, pharmaceutical company Cosmo said its placebo-controlled phase II trial of rifamycin 1% ...
For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...
PPAR agonists, antigen-specific immune tolerance therapies and IBAT inhibitors lead the PBC pipeline as companies target patients with an inadequate response to UDCA.Dublin, Oct. (GLOBE NEWSWIRE) -- ...
For the first time, a joint guideline from the American Gastroenterological Association (AGA) and American Association for ...
US gastroenterology and liver disease associations issued joint guidelines on diagnosing and treating primary biliary ...
The Russian Ministry of Health has added primary biliary cholangitis, a chronic autoimmune liver disease, to the list of orphan diseases. This is stated in a departmental document, which was reviewed ...
(Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic ...
A review of 5 investigational therapies with target action dates in November 2026, spanning neurology, gastroenterology, and oncology.
The 25-patient trial also showed improved joint mobility; Mirum plans to submit an application to extend use to ages 6 to ...
Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1Further upgraded ...
Seladelpar achieved the highest comparative ranking for biochemical response and ALP normalization in patients with PBC.
Patients with concurrent PBC and osteoporosis do not have an increased risk of major bone fracture vs patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results